Conviction
0 → 4
Conviction●●●●○4 of 5
Research target$257Snapshot target
Thesis statusSTRENGTHENEDLast reviewed 7/8/26
Market cap$140.81BSnapshot value
Research history
See all DHR changes ↗What changed
Target
— → $257
Thesis status
NEEDS_MORE_DATA → STRENGTHENED
Last reviewed
Not reviewed → 7/8/26
Target
— → $257
Conviction
1 → 4
Diversified life-science + diagnostics conglomerate. Cytiva/Pall bioprocessing gives Manufacture-layer exposure; Beckman/SCIEX/Leica give Measure exposure. Paid on volume across the whole competition.
Bioprocess cycle recovery (consumables growing ~10% YoY post-destocking); Masimo-adjacent acquisition expands monitoring; Danaher Business System margin execution.
Integration risk from acquisition strategy; bioprocess cyclicality (2023-24 destocking redux); segment dilution — bioprocess is a tailwind, not the whole thesis.
needs X/Reddit sentiment sweep
Snapshot · 7/8/26🟢 Lean-Bull · ins-$0.2M · 13F 13+/12- · short↓0.22
Snapshot · 7/8/26